Ohio State Navbar

Research

Diabetes Research


Boulevard Study

The purpose of this research study is to investigate the effects and safety of RO6867461 administered intravitreally in patients with diabetic macular edema (DME).

Diabetic macular edema (DME) is the term used for swelling in the small central part of the retina used for sharp straight ahead vision due to diabetes. The retina is a thin layer of tissue that lines the back of your eye. It is nourished by blood vessels that become affected by diabetes. 

The anti-VEGF drugs injected into the eye block a substance called vascular endothelial growth factor have been used to treat DME because abnormal levels of VEGF can be produced buy a retina affected by diabetes. These abnormal levels of VEGF can cause leakage of fluid from retinal blood vessels, which can cause swelling of the retina and potentially vision loss. There are several anti-VEGF drugs. All participants will receive either Lucentis
® or the experimental drug, RO6867461. No one will receive a placebo.


 

 

Panorama Study

Nonproliferative Diabetic Retinopathy (NPDR) is a leading cause of vision loss in patients with diabetes. NPDR occurs when the blood vessels within the retina (a tissue at the back of the eye) start to leak or bleed causing vision to be blurred and distorted. The retina is located at the back of the eye and controls central vision.

There are two types of diabetic retinopathy, nonproliferative and proliferative, each with varying stages of severity. In the earliest stages, the damaged blood vessels within the retina begin to leak. This leakage causes the retina to swell and vision to distort. Patients with type one or type two diabetes can develop NPDR. The chance of getting NPDR is higher if you have had diabetes for a long time or your blood sugar (glucose) has been uncontrolled.

The purpose of this study is to evaluate the effects of an investigational drug in research participants with diabetic retinopathy. An investigational drug is one which has not been approved by the U.S. Food and Drug Administration (FDA) for a particular use but is available in research studies like this one.

 

 

 

 

FOR MORE INFORMATION:

Call the research office at 614-293-5287 or email Research@osumc.edu.